>
Switch to:

Tekla Life Sciences Investors Research & Development

: $0.0 Mil (TTM As of Sep. 2020)
View and export this data going back to . Start your Free Trial

This is the expense the company spent on research and development. Tekla Life Sciences Investors's research and development for the six months ended in Sep. 2020 was $0.0 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2020 was $0.0 Mil.


Tekla Life Sciences Investors Research & Development Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Tekla Life Sciences Investors Annual Data
Sep17 Sep18 Sep19 Sep20
Research & Development 0.00 0.00 0.00 0.00

Tekla Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20
Research & Development Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tekla Life Sciences Investors Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported semi-annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Sep. 2020 was $0.0 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Tekla Life Sciences Investors  (NYSE:HQL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Tekla Life Sciences Investors Research & Development Related Terms


Tekla Life Sciences Investors Research & Development Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)